ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib

BACKGROUND: ROS1 rearrangements are validated drivers in lung cancer, which have been identified in a small subset (1–2%) of patients with non-small cell lung cancer (NSCLC). To date, 18 fusion genes of ROS1 have been identified in NSCLC. The ALK inhibitor (crizotinib) exhibits therapeutic effect ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Shuguang, Wang, Wenxian, Xu, Chunwei, Li, Xingliang, Ye, Junhui, Zhu, Youcai, Ge, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683537/
https://www.ncbi.nlm.nih.gov/pubmed/31382924
http://dx.doi.org/10.1186/s12885-019-5948-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683537/
https://www.ncbi.nlm.nih.gov/pubmed/31382924
http://dx.doi.org/10.1186/s12885-019-5948-y

Ejemplares similares